Biomarkers Consortium – The Performance of Novel Cardiac Biomarkers in the General U.S. Population

The Problem
Cardiovascular disease is one of the most lethal conditions in the United States, yet Researchers lack the tools needed to assess an individual’s risk of developing or dying from this disease.
The Solution
This project will establish “normal” reference levels of several biomarkers and determine these biomarkers’ ability to predict deaths from cardiovascular disease in the general U.S. population, as well as in various demographic subgroups.


The Biomarkers Consortium’s Novel Cardiac Biomarkers in the General US Population (the Cardiac Troponin Project) seeks to define the reference ranges, and to generate the epidemiologic basis, for the use of several significant novel cardiac and related biomarkers for cardiovascular risk stratification in the general U.S. population. The project will measure a panel of biomarkers in almost 30,000 individuals in a national study and will provide key reference data regarding novel biomarkers for cardiovascular risk stratification. This reference data will in turn inform U.S. clinical and laboratory guidelines for cardiovascular diseases.


  • Define the reference ranges of several biomarkers (i.e., hs-cTnT, hs-cTnI  and NT-proBNP) in a healthy subgroup of young adults (N=1,938) and describe age-, gender- and race-specific population values.
  • Characterize the associations of these biomarkers (i.e., hs-cTnT, hs-cTnI  and NT-proBNP) with cardiovascular and total mortality in the U.S. population without clinical cardiovascular disease and compare hs-cTnT to hs-cTnI head-to-head for their ability to predict mortality risk.

Results & Accomplishments

  • FNIH-Funded Study Finds 1 Out of 3 US Adults with Type 2 Diabetes Has Undetected Cardiovascular Disease. Read more
  • Peer reviewed publications and final dataset made publicly available on NHANES’ website


Associations of Glycated Albumin and HbA1c with Chronic Kidney Disease in US Adults. Hyunju Kim, Olive Tang, Casey M. Rebholz, Morgan E. Grams, Josef Coresh, Robert H. Christenson, and Elizabeth Selvin. JALM | 1–12 | 00:0 | 25 February 2022 Read more

Amelia S. Wallace1,2 | Mary R. Rooney1,2 | Tammy M. Brady3 |Justin B. Echouffo-Tcheugui4 | Robert Christenson5 | Morgan E. Grams1,2,4 | Elizabeth Selvin1,2I. The performance of glycated albumin as a biomarker of hyperglycemia and cardiometabolic risk in children and adolescents in the United States. Wiley. Received: 20 July 2021 Revised: 1 October 2021 Accepted: 23 October 2021 Read more

Michael Fang, Natalie Daya , Josef Coresh, Robert H. Christenson, and Elizabeth Selvin, Glycated Albumin for the Diagnosis of Diabetes in US Adults. Endocrinology and Metabolism. Clinical Chemistry 68:3, 413–421 (2022). Read more

Mary R. Rooney, Natalie Daya, Olive Tang, John William McEvoy, Josef Coresh,, Robert H. Christenson, and Elizabeth Selvin. Glycated Albumin and Risk of Mortality in the US Adult Population. Epidemiological Studies. Clinical Chemistry 68:3, 422–430 (2022). Read more

Caitlin W. Hicks, Dan Wang , Kunihiro Matsushita, John W. McEvoy, Robert Christenson, Elizabeth Selvin. Glycated albumin and HbA1c as markers of lower extremity disease in US adults with and without diabetes. Diabetes Research and Clinical Practice. 2022. 109212 Read more

Fang M, Wang D, Tang O, McEvoy JW, Echouffo-Tcheugui JB, Christenson RH, Selvin E. Subclinical Cardiovascular Disease in US Adults With and Without Diabetes. J Am Heart Assoc. 2023 Jun 6;12(11): e029083. Read more

John W. McEvoy, Natalie Daya, Olive Tang, Michael Fang, Chiadi E. Ndumele, Josef Coresh, Robert H. Christenson, and Elizabeth Selvin. High-sensitivity troponins and mortality in the general population. European Heart Journal (2023) 00, 1–11. Read more

Minhas AS, Echouffo-Tcheugui JB, Zhang S, Ndumele CE, McEvoy JW, Christenson R, Selvin E. High-Sensitivity Troponin T and I Among Pregnant Women in the US-The National Health and Nutrition Examination Survey, 1999-2004. JAMA Cardiol. 2023 Apr 1;8(4):406-408. Read more

Mu S, Echouffo-Tcheugui JB, Ndumele CE, Coresh J, Juraschek S, Brady T, McEvoy JW, Ozkan B, Tang O, Christenson RH, Selvin E. NT-proBNP Reference Intervals in Healthy U.S. Children, Adolescents, and Adults. J Appl Lab Med. 2023 Jul 5;8(4):700-712. Read more

McEvoy JW, Wang D, Brady T, Tang O, Ndumele CE, Coresh J, Christenson RH, Selvin E. Myocardial injury thresholds for 4 High-sensitivity troponin assays in a population-based sample of US children and adolescents. Circulation. 2023; 148:7–16. Read more

McEvoy JW, Tang O, Wang D, Ndumele CE, Coresh J, Christenson RH, Selvin E. Myocardial Injury Thresholds for 4 High-Sensitivity Troponin Assays in U.S. Adults. J Am Coll Cardiol. 2023 May 23;81(20):2028-2039. Read more

Minhas AS, Rooney MR, Fang M, Zhang S, Ndumele CE, Tang O, Schulman SP, Michos ED, McEvoy JW, Echouffo-Tcheugui J, Christenson R, Selvin E. Prevalence and Correlates of Elevated NT-proBNP in Pregnant Women in the General U.S. Population. JACC Adv. 2023 Mar;2(2):100265. Read more

McCarthy C, Vyas A, Januzzi J, et al. What Is a Normal Troponin, Anyway?∗ . J Am Coll Cardiol. 2023 May, 81 (20) 2040–2042. Read more

Aakre KM, Meex SJR, Mills NL. Cardiac Troponin Reporting in Children and Young Adults: Time to Change Clinical Practice. Circulation. 2023 Jul 4;148(1):17-19. Read more

de Lemos JA, Berry JD. Comparisons of multiple troponin assays for detecting chronic myocardial injury in the general population: redundant or complementary? Eur. Heart J. Volume 44, Issue 28, 21 July 2023, 2606–2608. Read more

Leave a comment

Your email address will not be published. Required fields are marked *